Patel Engg gains 12 per cent post positive Q1 result
Patel Engg gains 12 per cent post positive Q1 result

Patel Engg gains 12 per cent post positive Q1 result

Tanay Loya Article rating: 5.0

The share price of Patel Engineering Company jumped about 12 per cent on Thursday after the company reported profit of Rs. 36.2 crore for the quarter ended June 2018.

Cosmo Films launches CPP metalized film
Cosmo Films launches CPP metalized film

Cosmo Films launches CPP metalized film

Nidhi Jani Article rating: 5.0

This film has been specially designed to offer superior inter-layer bond strength for making multi-layer laminate structures, which in turn enhances barrier properties, said the company in a filing to the bourses.

Q1FY19 Result: Suven Life Sciences PAT jumps 31 per cent
Q1FY19 Result: Suven Life Sciences PAT jumps 31 per cent

Q1FY19 Result: Suven Life Sciences PAT jumps 31 per cent

Sanket Dewarkar Article rating: 5.0

Suven Life Sciences reported its results for the quarter ended June 30, 2018. The company’s standalone revenue for the quarter came in at Rs. 191.66 crore, registering 35.9 per cent yoy increase. This was mainly driven by a jump in revenue from the manufacturing segment by 35.2 per cent yoy.

DSIJ Explains: Turkey currency crisis
DSIJ Explains: Turkey currency crisis

DSIJ Explains: Turkey currency crisis

Shashikant Singh Article rating: 5.0

Lira, the currency of Turkey, has fallen by 40 per cent the year till date with a fear of contagion being spread to other emerging countries including India.

NBCC jumps 4 per cent on SAIL order win
NBCC jumps 4 per cent on SAIL order win

NBCC jumps 4 per cent on SAIL order win

Nidhi Jani Article rating: 5.0

 The company has an order book of more than Rs. 80,000 crore in hand. This leads to book/bill ratio of 13x which is highest amongst infrastructure companies.

15 per cent equity schemes offer more than 25 per cent returns
15 per cent equity schemes offer more than 25 per cent returns

15 per cent equity schemes offer more than 25 per cent returns

Nikhil Desai Article rating: 4.0

Double-digit returns in the longer term is what most mutual fund investors desire for. Mutual fund investments are meant for the long-term wealth creation and investors usually invest in the schemes for achieving long-term financial goals.

Sun Pharma receives USFDA approval for ophthalmic solution
Sun Pharma receives USFDA approval for ophthalmic solution

Sun Pharma receives USFDA approval for ophthalmic solution

Shohini Nath Article rating: 5.0

Sun Pharmaceutical Industries Limited has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the US Food and Drug Administration (FDA). CEQUA is indicated to increase the tear production in patients that suffer from the condition of Keratoconjunctivitis sicca that is, dry eyes.

KNR Construction mulls to monetise HAM projects
KNR Construction mulls to monetise HAM projects

KNR Construction mulls to monetise HAM projects

Amir Shaikh Article rating: 5.0

Road and infrastructure builder, KNR Construction may sell four of its HAM (Hybrid Annuity Model) projects, reported a leading business daily. The company is said to be in talks with private equity firm Brookfield and Cube Highway for the deal.

RSS
First32393240324132423244324632473248Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR